Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene

Acta Biochimica et Biophysica Sinica

Volumn 35, Issue 12, 2003, Pages 1066-1071

  Zhuo, Ming ^a   Xu, De Hua ^a   Cao, Lei ^a   Xu, Ling Fei ^a   Yu, Fu Rong ^a   Zheng, Zhong Cheng ^a   Liu, Xin Yuan ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Gene therapy; Glial cell; Parkinson's disease; SV40 large T antigen; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL BASED GENE THERAPY; CELL IMMORTALIZATION; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; FETUS; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; GLIA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LONG TERM CARE; NONHUMAN; NUDE MOUSE; PARKINSON DISEASE; PARKINSONISM; PROTEIN EXPRESSION; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CELL LINE, TRANSFORMED; CORPUS STRIATUM; DOPAMINE; FETUS; GENE THERAPY; HUMANS; MICE; MICE, NUDE; NEUROGLIA; PARKINSON DISEASE, SECONDARY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS MUSCULUS;

EID: 1642315518     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Duvoisin RC. Overview of Parkinson' s disease. Ann NY Acad Sci, 1992, 648: 187-193
2. Raymon HK, Thode S, Gage FH Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol, 1997, 144(1): 82-91
3. Schuh LA, Bennett JP Jr. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology, 1993, 43: 1545-1550
4. Obeso JA, Grandas F, Herroero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neursci, 1994, 6: 889-897
5. Gage FH. Cell therapy. Nature, 1998, 392(6679 Suppl): 18-24
6. Wolff JA, Fisher LJ, Xu L, Jinnah HA, Langlais PJ, Iuvone PM, O' Malley KL et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA, 1989, 86(22): 9011-9014
7. Cao L, Zheng ZC, Zhao YC, Jiang ZH, Liu ZG, Chen SD, Zhou CF et al. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther, 1995, 6: 1497 -1501
8. Cao L, Zhao YC, Jiang ZH, Xu DH, Liu ZG, Chen SD, Liu XY et al. Long-term phenotypic correction of rodent hemiparkinsonism by gene therapy using genetically modified myoblasts. Gene Ther, 2000, 7: 445-449
9. Bacci A, Verderio C, Pravettoni E, Matteoli M. The role of glial cells in synaptic function. Philos Trans R Soc Lond Biol Sci, 1995, 354 (1381): 403-409
10. Clarkson ED, la Rosa FG, Edwards-Prasad J, Kumar S, Kumar A, Cole W, Freed CR et al. Brain contains inhibiting factors specific to the large T-antigen gene. Cancer Lett, 1998, 122(1-2): 31-36
11. la Rose FG, Adams FS, Krause GE, Meyers AD, Edwards-Prasad J, Kumar R, Freed CR et al. Inhibition of proliferation and expression of T antigen in SV40 larger T-antigen gene-induced immortalized cell following transplantations. Cancer Lett, 1997, 113: 55-59
12. Levine RA, Miller LP, Lovenberg W. Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis. Science, 1981, 214(4523): 919-921
13. Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ. Aromatic L-amino acid decarboxylase in rat corpus striatum: Implications for action of L-dopa in parkinsonism. Neurology, 1981, 31(6): 651-655
14. Kaddis FG, Clarkson ED, Weber MJ, Vandenbergh DJ, Donovan DM, Mallet J, Horellou P et al. Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: Neurochemical effects. J Neurochem, 1997, 68(4): 1520-1526
15. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, Mizukami H et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther, 2000, 11(11): 1509-1519
16. Juorio AV, Li XM, Walz W, Paterson IA. Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res, 1993, 626(1-2): 306-309
17. Tacconi MT. Neuronal death: Is there a role for astrocytes? Neurochem Res, 1998, 23(5): 759-775
18. Muller DP. Neurological disease. Adv Pharmacol, 1997, 38: 557-580
19. Schwarz EJ, Alexander GM, Prockop DJ, Azizi SA. Multipotential marrow stromal cells transduced to produce L-DOPA: Engraftment in a rat model of Parkinson disease. Hum Gene Ther, 1999, 10(15): 2539-2549
20. Shingo T, Date I, Yoshida H, Ohmoto T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J Neurosci Res, 2002, 69(6): 946-954
21. HogenEsch RI, Koopmans J, Copray JC, van Roon WM, Kema I, Molenaar G, Go KG et al. Fetal porcine ventral mesencephalon graft. Determination of the optimal gestational age for implantation in Parkinsonian patients. Exp Brain Res, 2000, 132(3): 345-350
22. ThyagaRajan S, MohanKumar PS, Quadri SK. Cyclic changes in the release of norepinephrine and dopamine in the medial basal hypothalamus: Effects of aging. Brain Res, 1995, 689(1): 122-128